相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The safety of vedolizumab for ulcerative colitis and Crohn's disease
Jean-Frederic Colombel et al.
GUT (2017)
Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort
Krisztina B. Gecse et al.
JOURNAL OF CROHNS & COLITIS (2016)
Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations
J. Sieczkowska et al.
JOURNAL OF CROHNS & COLITIS (2016)
Impact of patient characteristics on the clinical efficacy of mongersen (GED-0301), an oral Smad7 antisense oligonucleotide, in active Crohn's disease
G. Monteleone et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
Parambir S. Dulai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
Prevalence of hepatitis B and clinical outcomes in inflammatory bowel disease patients in a viral-endemic region
Heyson C. H. Chan et al.
BMC GASTROENTEROLOGY (2016)
Long-term Outcomes of Thalidomide Therapy for Adults With Refractory Crohn's Disease
Marion Simon et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents
Pauline Wils et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Early Course of Inflammatory Bowel Disease in a Population-Based Inception Cohort Study From 8 Countries in Asia and Australia
Siew C. Ng et al.
GASTROENTEROLOGY (2016)
Biosimilars in Crohn's Disease and Ulcerative Colitis
Douglas C. Wolf
INFLAMMATORY BOWEL DISEASES (2016)
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
Sam Khorrami et al.
INFLAMMATORY BOWEL DISEASES (2016)
Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis
Julian Panes et al.
JOURNAL OF CROHNS & COLITIS (2016)
Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients
Jorgen Jahnsen
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2016)
Differences in the public medical insurance systems for inflammatory bowel disease treatment in Asian countries
Shu Chen Wei
INTESTINAL RESEARCH (2016)
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes
Julian Panes et al.
BMC GASTROENTEROLOGY (2015)
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up
R. G. Langley et al.
BRITISH JOURNAL OF DERMATOLOGY (2015)
Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
Henit Yanai et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2015)
Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn's disease and ulcerative colitis - experiences from a single center
Klaudia Farkas et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study
Yoon Suk Jung et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Biologic agents for IBD: practical insights
Silvio Danese et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Mongersen, an Oral SMAD7 Antisense Oligonucleotide, and Crohn's Disease
Giovanni Monteleone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Increased risk of mycobacterial infections associated with anti-rheumatic medications
Sarah K. Brode et al.
THORAX (2015)
Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
Nynne Nyboe Andersen et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
Sang Hyoung Park et al.
Expert Review of Gastroenterology & Hepatology (2015)
Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study
Nynne Nyboe Andersen et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Long-term outcomes of thalidomide in refractory Crohn's disease
M. E. Gerich et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
The biosimilar road in inflammatory bowel disease: The right way?
Gionata Fiorino et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2014)
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease
William J. Sandborn et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
Bruce E. Sands et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF alpha therapy: results from the COIN study
Mirthe Emilie van der Valk et al.
GUT (2014)
Prevalence and factors related to hepatitis B and C infection in inflammatory bowel disease patients in China: A retrospective study
Mei Lan Huang et al.
JOURNAL OF CROHNS & COLITIS (2014)
Vedolizumab for induction and maintenance of remission in ulcerative colitis
Stephen J. Bickston et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2014)
Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries
Valentin Brodszky et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases
M. Rinaudo-Gaujous et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Infectious and Malignant Complications of TNF Inhibitor Therapy in IBD
Laura E. Targownik et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn's and Colitis Epidemiology Study
Siew C. Ng et al.
GASTROENTEROLOGY (2013)
Effect of Thalidomide on Clinical Remission in Children and Adolescents With Refractory Crohn Disease A Randomized Clinical Trial
Marzia Lazzerini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: A prospective population-based study
Zhirong Zeng et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2013)
Vedolizumab, a monoclonal antibody to the gut homing 01.4137 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype
Catherine Milch et al.
JOURNAL OF NEUROIMMUNOLOGY (2013)
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease
Mehmet Coskun et al.
PHARMACOLOGICAL RESEARCH (2013)
Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
Gary R. Lichtenstein et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFα agents: A retrospective analysis of 49 cases
Han Hee Ryu et al.
CLINICAL RHEUMATOLOGY (2012)
Deciphering the mystery of thalidomide teratogenicity
Takumi Ito et al.
CONGENITAL ANOMALIES (2012)
Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates
Eric R. Fedyk et al.
INFLAMMATORY BOWEL DISEASES (2012)
Management of inflammatory bowel disease in pregnancy
Severine Vermeire et al.
JOURNAL OF CROHNS & COLITIS (2012)
Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
William J. Sandborn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
On the Regulatory Approval Pathway of Biosimilar Products
Jun Wang et al.
PHARMACEUTICALS (2012)
Assessing Response and Loss of Response to Biological Therapies in IBD
Henit Yanai et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
Jean Frederic Colombel et al.
GASTROENTEROLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Inflammatory Bowel Disease-Attributable Costs and Cost-effective Strategies in the United States: A Review
K. T. Park et al.
INFLAMMATORY BOWEL DISEASES (2011)
Discovery and mechanism of ustekinumab A human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders
Jacqueline M. Benson et al.
MABS (2011)
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
James H. Kim et al.
TOXICOLOGICAL SCIENCES (2011)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures
S. M. MCHUGH et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy
C. Loras et al.
GUT (2010)
Discovery of CP-690,550: A Potent and Selective Janus Kinase (JAK) Inhibitor for the Treatment of Autoimmune Diseases and Organ Transplant Rejection
Mark E. Flanagan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases
David B. Clifford et al.
LANCET NEUROLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases (vol 9, pg 438, 2010)
D. B. Clifford et al.
LANCET NEUROLOGY (2010)
Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease
Kai Wang et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2009)
The Safety and Efficacy of a JAK Inhibitor in Patients With Active Rheumatoid Arthritis Results of a Double-Blind, Placebo-Controlled Phase IIa Trial of Three Dosage Levels of CP-690,550 Versus Placebo
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2009)
Risk of Lymphoma Associated With Combination Anti-Tumor Necrosis Factor and Immunomodulator Therapy for the Treatment of Crohn's Disease: A Meta-Analysis
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease
Fabian Schnitzler et al.
INFLAMMATORY BOWEL DISEASES (2009)
Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Pharmacologic Effect of CP-690,550 in Patients With Psoriasis
Mary G. Boy et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-alpha(4)beta(7) Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
Dulce Soler et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease
William J. Sandborn et al.
GASTROENTEROLOGY (2008)
FDA's Proposed Rule for Pregnancy and Lactation Labeling: Improving Maternal Child Health Through Well-informed Medicine Use
Karen B. Feibus
JOURNAL OF MEDICAL TOXICOLOGY (2008)
Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies
S. Plamondon et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-β1-mediated suppression of colitis
Monica Boirivant et al.
GASTROENTEROLOGY (2006)
Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials
T Bongartz et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Brief report - Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease
G Van Assche et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Infliximab as rescue therapy in severe to moderately severe ulcerative colitis:: A randomized, placebo-controlled study
G Järnerot et al.
GASTROENTEROLOGY (2005)
Infliximab maintenance therapy for fistulizing Crohn's disease
BE Sands et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor
PS Changelian et al.
SCIENCE (2003)
Long-term evolution of disease behavior of Crohn's disease
J Cosnes et al.
INFLAMMATORY BOWEL DISEASES (2002)
Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease
J Bauditz et al.
GUT (2002)
Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent
J Keane et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: A pilot study
BE Sands et al.
INFLAMMATORY BOWEL DISEASES (2001)
分享论文
